Lv1
10 积分 2025-09-08 加入
Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic Leukemia
1个月前
已完结
Analysis of factors predicting re- sponse of 254 patients received CD19 CAR-T cell therapy for relapsed/refractory (R/R) B-ALL
1个月前
已关闭
Post-chimeric antigen receptor T- cell therapy haematopoietic stem cell transplantation for 52 cases with refractory/relapsed B-cell acute lymphoblastic leukaemia
1个月前
已完结
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL
1个月前
已完结
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
1个月前
已完结
Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy
1个月前
已完结
Tandem CD19/CD22 CAR T-Cell Therapy as First-Line Treatment for Adult Patients With High-Risk Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
1个月前
已完结
Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL
1个月前
已关闭
Very Promising Results of the Dose Dense (D-D) Mini-Hyper-CVD-Inotuzumab-Blinatumomab Phase 2 Trial in Patients with Relapsed-Refractory Acute Lymphoblastic Leukemia
1个月前
已完结
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
1个月前
已完结
皖公网安备34019202002308
